Overview
Oligodendroglioma is a rare malignant brain tumor representing approximately 5% of all gliomas, characterized by the presence of neoplastic oligodendrocytes 1.Diagnosis
Clinical Presentation: Sudden onset of neurological deficits such as visual field loss, disc edema, and esotropia 1.
Imaging: MRI is essential for localization and characterization of the tumor 1.
Biopsy and Pathology: Histopathological examination with immunohistochemical markers like GFAP, MAG, MBP, and CA C aids in diagnosis 2.
Grading: Typically classified using the World Health Organization (WHO) grading system (I, II, III) based on cellular atypia and mitotic activity 2.Management
Primary Treatment: Surgery for resection when feasible 1.
Radiation Therapy: Post-surgical radiotherapy is standard for higher-grade tumors 1.
Chemotherapy: Temozolomide is often used, especially in recurrent or higher-grade oligodendrogliomas 1.
Targeted Therapy: Not specifically detailed in abstracts, but may be considered based on molecular profiling 2.Special Populations
Pediatrics: Presentation can occur in children, as seen in a 12.5-year-old patient with neurological symptoms 1.
Metastatic Behavior: Rarely, oligodendroglioma can metastasize to bone marrow, presenting as leukoerythroblastic anemia 3.
Familial Cases: Occurrence in familial settings has been reported, suggesting potential genetic predisposition 4.Key Recommendations
Surgical Resection: For eligible patients, surgical resection should be considered as primary treatment 1 (Evidence: Strong).
Post-Surgical Radiotherapy: Recommended for patients with higher-grade oligodendrogliomas to improve outcomes 1 (Evidence: Strong).
Use of Temozolomide: Consider temozolomide in the management of recurrent or higher-grade oligodendrogliomas 1 (Evidence: Moderate).
Monitor for Metastasis: Given the rare but documented cases of bone marrow metastasis, vigilant monitoring is advised 3 (Evidence: Weak).
Genetic Counseling: Consider genetic counseling for families with multiple cases of oligodendroglioma 4 (Evidence: Expert opinion).References
1 Raciti-Daurio C, Caruso J. Oligodendroglioma--a case presentation. Optometry and vision science : official publication of the American Academy of Optometry 1990. link
2 Nakagawa Y, Perentes E, Rubinstein LJ. Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers. Acta neuropathologica 1986. link
3 Newman HF, Howard GC, Reid PM. Metastatic oligodendroglioma presenting as a leukoerythroblastic anaemia. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1985. link
4 Roosen N, De La Porte C, Van Vyve M, Solheid C, Selosse P. Familial oligodendroglioma. Case report. Journal of neurosurgery 1984. link